Business
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma (NASDAQ:SBFM) is quickly establishing which side of that line it's on. After scoring another major regulatory ...
About this update from Sunshine Biopharma Inc.
[{"type":"text","content":"FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma (NASDAQ:SBFM) is quickly establishing which side of that line it's on. After scoring another major regulatory win, that position certainly isn't one of many in the crowd. On Tuesday, the company announced that it had secured Health Canada authorization to commercialize domperidone through its Nora Pharma subsidiary, a milestone that not only expands its commercial reach but also validates its growing track record of revenue-generating execution.","length":599,"tagName":"p"},{"type":"text","content":"It's a potentially enormous win, particularly for a microcap biotech trading with a market cap under $10 million. Health Canada's decision opens access to one of the most respected and tightly regulated pharmaceutical markets in the world. But the significance runs deeper than geography. This approval gives Sunshine entry into a market segment that moves fast, scales efficiently, and rewards consistency more than marketing.","length":435,"tagName":"p"},{"type":"text","content":"For Sunshine, the math is simple but powerful. Global domperidone sales are projected to reach $1.36 billion by the end of 2025. North America accounts for roughly 39% of that, and Canada represents nearly 17% of the North American share. That translates to a $200 million-plus opportunity in Sunshine's own backyard. Not theoretical, not futuristic, but tangible and accessible now. It's a win that fits right into Sunshine's playbook: stack measurable progress, compound it, and let the results speak louder than the hype.","length":536,"tagName":"p"},{"type":"text","content":"A Pattern of Reaching Milestones","length":32,"tagName":"p"},{"type":"text","content":"On that front, there's plenty to value. This newest marketing approval isn't a one-off regulatory milestone; it's part of a bigger pattern of creating value drivers. Nora Pharma's methodical approach to the generics market has created a base of recurring revenue and regulatory credibility, enabling each new launch to be faster, smoother, and more efficient. Domperidone isn't just another product in that lineup. It's the kind of green light that turns operational momentum into market momentum. And in biotech, that...